Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 12, 1999, Pages 3025-3029

  Moore, Katy H P ^a   Yuen, Geoffrey J ^a   Hussey, Elizabeth K ^a   Pakes, Gary E ^a   Eron Jr , Joseph J ^b   Bartlett, John A ^c  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; AGE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RACE DIFFERENCE; SEX DIFFERENCE;

EID: 0032795718     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.12.3025     Document Type: Article

References (23)

1. Angel, J. B., E. K. Hussey, S. T. Hall, K. H. Donn, D. M. Morris, J. P. McCormack, J. S. G. Montaner, and J. Ruedy. 1993. Pharmacokinetics of 3TC (GR109714X) administered with and without food to HIV-infected patients. Drug Investig. 6:70-74.
2. Bartlett, J. A., S. L. Benoit, V. A. Johnson, J. B. Quinn, G. E. Sepulveda, W. C. Ehmann, C. Tsoukas, M. A. Fallon, P. L. Self, and M. Rubin for The North American HIV Working Party. 1996. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. Ann. Intern. Med. 125:161-172.
3. Beal, S. L., and L. B. Sheiner. 1989. NONMEM user's guide. University of California at San Francisco, San Francisco.
4. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
5. + cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
6. Gitterman, S. R., G. L. Drusano, M. J. Egorin, H. C. Standiford, and The Veterans Administration Cooperative Studies Group. 1990. Population pharmacokinetics of zidovudine. Clin. Pharmacol. Ther. 48:161-167.
7. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, G. Gonzalez, D. McManon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
8. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, Jr., J. E. Feinberg, H. H. Balfour, Jr., L. R. Deyton, J. A. Chodakewitz, and M. A. Fischl for The AIDS Clinical Trials Group 320 Study Team. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725-733.
9. Harker, A. J., G. L. Evans, A. E. Hawley, and D. M. Morris. 1994. High-performance liquid chromatographic assay for 2′-deoxy-3′-thiacytidine in human serum. J. Chromatogr. B 657:227-232.
10. Heald, A. E., P. H. Hsyu, G. J. Yuen, P. Robinson, P. Mydlow, and J. A. Bartlett. 1996. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob. Agents Chemother. 40:1514-1519.
11. Horton, C. M., G. Yuen, D. M. Mikolich, A. Fisher, K. Rana, P. Mydlow, and M. N. Dudley. 1994. Pharmacokinetics (PK) of oral lamivudine administered alone and with oral zidovudine (ZDV) in asymptomatic patients with human immunodeficiency virus (HIV) infection. Clin. Pharmacol. Ther. 55:198. (Abstract.)
12. Johnson, M. A., K. H. P. Moore, G. J. Yuen, A. Bye, and G. E. Pakes. 1999. A review of the clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. 36:1-26.
13. Moore, K. H. P., S. Shaw, A. L. Laurent, P. Lloyd, B. Duncan, D. M. Morris, M. J. O'Mara, and G. E. Pakes. 1999. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J. Clin. Pharmacol. 39:593-605.
14. Moore, K. H. P., G. J. Yuen, and E. K. Hussey. 1997. Analysis of potential differences in lamivudine (3TC) disposition using population pharmacokinetics from two phase III clinical trials in HIV-infected patients, abstr. P1.54, p. 168-169. In Abstract book of the National Conference on Women and HIV.
15. Moore, K. H. P., G. J. Yuen, R. H. Raasch, J. J. Eron, D. Martin, P. K. Mydlow, and E. K. Hussey. 1996. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin. Pharmacol. Ther. 59:550-558.
16. Pai, S. M., U. A. Shukla, T. H. Grasela, C. A. Knupp, R. Dolin, F. T. Valentine, C. McLaren, H. A. Liebman, R. R. Martin, K. A. Pittman, and R. H. Barbhaiya. 1992. Population pharmacokinetic analysis of didanosine (2′,3′-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex. J. Clin. Pharmacol. 32: 242-247.
17. Pluda, J. M., T. P. Cooley, J. S. G. Montaner, L. E. Shay, N. E. Reinhalter, S. N. Warthan, J. Ruedy, H. M. Hirst, C. A. Vicary, J. B. Quinn, G. J. Yuen, M. A. Wainberg, M. Rubin, and R. Yarchoan. 1995. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 171:1438-1447.
18. Rana, K. Z., C. M. Horton, G. J. Yuen, P. E. Pivarnick, D. M. Mikolich, A. E. Fisher, P. K. Mydlow, and M. N. Dudley. 1994. Effect of lamivudine on zidovudine pharmacokinetics in asymptomatic HIV-1-infected individuals, abstr. A62, p. 83. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
19. Sheiner, L. B., and S. L. Beal. 1983. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J. Pharmacokinet. Biopharm. 11:303-309.
20. van Leeuwen, R., J. M. A. Lange, E. K. Hussey, K. H. Donn, S. T. Hall, A. J. Harker, P. Jonker, and S. A. Danner. 1992. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 6:1471-1475.
21. Whiting, B., A. W. Kelman, and J. Grevel. 1986. Population pharmacokinetics: theory and clinical application. Clin. Pharmacokinet. 11:387-401.
22. Yuen, G. J., D. M. Morris, P. K. Mydlow, S. Haidar, S. T. Hall, and E. K. Hussey. 1995. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J. Clin. Pharmacol. 35:1174-1180.
23. Yuen, G. Y., S. Benoit, M. Rubin, et al. 1996. Population pharmacokinetics of lamivudine in HIV-infected patients: results from two phase III clinical trials. Clin. Pharmacol. Ther. 59:144. (Abstract.)